Parkinson's disease
Conditions
Interventions
Control group:Cnventional drugs
Baduanjin group:Conventional drugs and Baduanjin
Sponsors
The Third Affiliated Hospital of Xinxiang Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of MDS-UPDRS Parkinson's disease; 2. Parkinson's disease patients with Hoehn-Yahr (HY) grade of 1-2.5 who could walk independently; 3. Sign informed consent; 4. Mini-mental state examination (MMSE) >= 24; 5. To receive a stable dose of anti-Parkinson drugs for at least 2 weeks before the start of the study, and to maintain this dose during treatment; 6. At least 1 year without regular physical exercise (3 months, 3 to 4 times a week, 30 minutes each time is regarded as the minimum standard of regular physical exercise).
Exclusion criteria
Exclusion criteria: 1. Secondary Parkinson's disease syndrome and other superimposed syndromes; 2. Patients with stroke, head trauma, hydrocephalus, brain tumors, increased intracranial pressure and history of intracranial surgery; 3. Patients with metal foreign bodies, cardiac pacemakers, cardiac stents, cochlear implants, etc.; 4. Those who could not cooperate with resting-state functional magnetic resonance scanning and exercise intervention program; 5. Patients with alcohol dependence and central nervous system drug dependence; 6. There were serious organic lesions in heart, liver, kidney and other organs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Unified Parkinson's disease rating scale III, UPDRS III;Berg balance scale, BBS;Parkinson's sleep scale 2, PDSS-2;Interleukin-6, IL-6;Interleukin-1 beta, IL-1ß; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-motor symptoms scale, NMSS;Minimum mental state examination, MMSE;Montreal cognitive assessment, MoCA;Hamilton depression scale, HAMD;Hamilton anxiety scale, HAMA;King's PD pain scale, KPPS;Pittsburgh sleep quality index, PSQI;The scale for outcomes in PD for au tonomic symptoms, SCOPA-AUT;The 39-Item Parkinson's disease questionnaire, PDQ-39;Olfactory detection results;Gait parameter;Resting-state funetional magnetic resonance imaging;Brain-derived neurotrophic factor, BDNF;5-hydroxytryptamine, 5-HT;Dopamine, DA; | — |
Countries
China
Contacts
Public ContactHongxia Xing
The Third Affiliated Hospital of Xinxiang Medical University
Outcome results
None listed